Ad disclosure
Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Pfizer Inc. (NYSE:PFE)
Stock Price:
$43.45
+1.35
(3.21%)
Updated
Jul 28, 2021 08:02 PM GMT+0000
Overview
Financials
Statistics
Profile
Chart
| Market Cap | 243.22B |
|---|---|
| Revenue | 44.46B |
| Gross Profit | 33.94B |
| Shares Out | 5.60B |
| EPS (ttm) | 1.96 |
| PE Ratio | 21.2500 |
| Forward PE | 56.5101 |
| Dividend Rate (ttm) | 1.5169 |
| Dividend Yield | 0.0360 |
| Trading Day | Jul 28 |
|---|---|
| Last Price | $43.45 |
| Previous Close | $42.10 |
| Change ($) | 1.35 |
| Change (%) | 3.21% |
| Day's Open | 42.45 |
| Day's Range | 42.25 - 43.74 |
| Day's Volume | 53.40M |
| 52 Week Range | 33.03 - 43.74 |
About
Country
United States
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Employees
78,500
CEO
Albert Bourla
Address
235 E 42nd St
New York
New York
10017-5703
New York
New York
10017-5703
Phone
12125732323
Website
www.pfizer.com
Ticker Symbol
PFE
Exchange
New York Stock Exchange
Reporting Currency
USD
Pfizer Inc. earnings reports (2020)
| Q3 2020 | Q2 2020 | Q1 2020 | |
|---|---|---|---|
| Actual EPS | 0.72 | 0.78 | 0.8 |
| Consensus EPS | 0.71 | 0.68 | 0.73 |
| Announce Time | BTO | BTO | BTO |
| Number of Estimates | 13 | 10 | 9 |
| EPS Surprise Dollar | 0.01 | 0.1 | 0.07 |
| EPS Report Date | 27-10-2020 | 28-07-2020 | 28-04-2020 |
| Fiscal End Date | 30-09-2020 | 30-06-2020 | 31-03-2020 |
| Year Ago | 0.75 | 0.8 | 0.85 |
| Year Ago % Change | -4% | -2.5% | -5.88% |
Pfizer Inc. earnings reports (2019)
| Q4 2019 | Q3 2019 | Q2 2019 | |
|---|---|---|---|
| Actual EPS | 0.55 | 0.75 | 0.8 |
| Consensus EPS | 0.58 | 0.62 | 0.75 |
| Announce Time | BTO | BTO | BTO |
| Number of Estimates | 11 | 10 | 10 |
| EPS Surprise Dollar | -0.03 | 0.13 | 0.05 |
| EPS Report Date | 28-01-2020 | 29-10-2019 | 29-07-2019 |
| Fiscal End Date | 31-12-2019 | 30-09-2019 | 30-06-2019 |
| Year Ago | 0.64 | 0.78 | 0.81 |
| Year Ago % Change | -14.06% | -3.85% | -1.23% |
Pfizer Inc. income statements (2020) (USD)
| November 2020 | June 2020 | June 2020 | March 2020 | |
|---|---|---|---|---|
| Total Revenue | 12.13B | 11.80B | 11.80B | 12.03B |
| Cost of Revenue | 2.53B | 3.17B | 3.17B | 3.25B |
| Gross Profit | 9.60B | 8.63B | 8.63B | 8.78B |
| Research & Development | 2.36B | 2.13B | 2.13B | 1.73B |
| Selling General & Admin | 3.02B | 2.97B | 2.97B | 2.86B |
| Operating Expense | 8.80B | 8.27B | 8.27B | 7.84B |
| Operating Income | 3.33B | 3.53B | 3.53B | 4.19B |
| Other Income Expense Net | 0 | 419M | 419M | -308M |
| EBIT | 3.33B | 3.53B | 3.53B | 4.19B |
| Interest Income | 0 | 372M | 372M | 390M |
| Pretax Income | 2.18B | 3.95B | 3.95B | 3.89B |
| Income Tax | -26M | 519M | 519M | 475M |
| Minority Interest | 8M | 8M | 8M | 9M |
| Net Income | 2.19B | 3.43B | 3.43B | 3.40B |
| Net Income Basic | 2.19B | 3.43B | 3.43B | 3.40B |
Pfizer Inc. income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | 12.69B | 12.68B | 13.26B | 13.12B |
| Cost of Revenue | 3.62B | 3.79B | 3.74B | 3.59B |
| Gross Profit | 9.07B | 8.89B | 9.53B | 9.52B |
| Research & Development | 2.81B | 2.28B | 1.83B | 1.70B |
| Selling General & Admin | 4.21B | 3.24B | 3.49B | 3.33B |
| Operating Expense | 10.64B | 9.31B | 9.06B | 8.62B |
| Operating Income | 2.04B | 3.37B | 4.20B | 4.50B |
| Other Income Expense Net | -3.55B | 7.36B | -62M | -176M |
| EBIT | 2.04B | 3.37B | 4.20B | 4.50B |
| Interest Income | 415M | 409M | 389M | 361M |
| Pretax Income | -1.51B | 10.73B | 4.14B | 4.32B |
| Income Tax | -1.18B | 3.05B | -0.92B | 433M |
| Minority Interest | 10M | 4M | 10M | 6M |
| Net Income | -337M | 7.68B | 5.05B | 3.88B |
| Net Income Basic | -337M | 7.68B | 5.05B | 3.88B |
Pfizer Inc. income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | 13.98B | 13.30B | 13.47B | 12.91B |
| Cost of Revenue | 4.30B | 3.93B | 4.09B | 3.73B |
| Gross Profit | 9.68B | 9.37B | 9.38B | 9.18B |
| Research & Development | 2.44B | 2B | 1.79B | 1.74B |
| Selling General & Admin | 3.99B | 3.48B | 3.53B | 3.40B |
| Operating Expense | 10.72B | 9.40B | 9.40B | 8.86B |
| Operating Income | 3.26B | 3.90B | 4.06B | 4.05B |
| Other Income Expense Net | -4.2B | 281M | 464M | 79M |
| EBIT | 3.26B | 3.90B | 4.06B | 4.05B |
| Interest Income | 370M | 310M | 326M | 310M |
| Pretax Income | -0.95B | 4.18B | 4.53B | 4.13B |
| Income Tax | -563M | 66M | 648M | 556M |
| Minority Interest | 11M | 8M | 7M | 9M |
| Net Income | -394M | 4.11B | 3.87B | 3.56B |
| Net Income Basic | -394M | 4.11B | 3.87B | 3.56B |
Pfizer Inc. income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | 13.70B | 13.17B | 12.90B |
| Cost of Revenue | 4.39B | 3.96B | 3.81B |
| Gross Profit | 9.32B | 9.21B | 9.08B |
| Research & Development | 2.30B | 1.85B | 1.77B |
| Selling General & Admin | 4.53B | 3.48B | 3.41B |
| Operating Expense | 11.21B | 9.29B | 8.99B |
| Operating Income | 2.49B | 3.88B | 3.90B |
| Other Income Expense Net | -1.54B | -296M | -88M |
| EBIT | 2.49B | 3.88B | 3.90B |
| Interest Income | 329M | 320M | 312M |
| Pretax Income | 0.95B | 3.59B | 3.82B |
| Income Tax | -11.34B | 727M | 739M |
| Minority Interest | 15M | 18M | 5M |
| Net Income | 12.27B | 2.84B | 3.07B |
| Net Income Basic | 12.27B | 2.84B | 3.07B |
Pfizer Inc. balance sheet (2020) (USD)
| November 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Current Cash | 10.50B | 1.80B | 2.15B |
| Receivables | 10.01B | 9.13B | 9.88B |
| Inventory | 9.30B | 8.56B | 8.42B |
| Current Assets | 47.74B | 46.42B | 34.74B |
| Other Current Assets | 6.52B | 5.94B | 6.08B |
| Short Term Investments | 6.52B | 20.99B | 8.20B |
| Long Term Investments | 131.24B | 18.72B | 18.22B |
| Property/Plant Equipment | 14.40B | 14.11B | 14.04B |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 30.93B | 33.54B | 34.46B |
| Tangible Assets (Net) | -25.57B | -152.77B | -152.18B |
| Other Assets | 7B | 4.33B | 4.17B |
| Total Assets | 178.98B | 177.93B | 166.34B |
| Accounts Payable | 4.14B | 3.87B | 3.97B |
| Other Current Liabilities | 16.65B | 14.32B | 12.76B |
| Total Current Liabilities | 34.15B | 32.72B | 33.89B |
| Total Liabilities | 113.73B | 113.37B | 101B |
| Long Term Debt | 49.79B | 50.53B | 36.28B |
| Current Long Term Debt | 13.36B | 1.48B | 337M |
| Minority Interest | 236M | 8M | 9M |
| Common Stock | 88.63B | 5.55B | 5.55B |
| Treasury Stock | -110.98B | 110.98B | 111.01B |
| Retained Earnings | 100.28B | 100.20B | 101B |
| Capital Surplus | N.A | 87.89B | 87.68B |
| Shareholder Equity | 65.26B | 64.34B | 65.03B |
| Other Liabilities | N.A | N.A | N.A |
Pfizer Inc. balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 1.31B | 2.79B | 1.78B | 1.94B |
| Receivables | 8.72B | 9.44B | 9.79B | 9.60B |
| Inventory | 8.28B | 8.22B | 8.23B | 8.03B |
| Current Assets | 32.80B | 33.46B | 47.07B | 45.29B |
| Other Current Assets | 5.97B | 6.71B | 16.14B | 16.04B |
| Short Term Investments | 8.53B | 6.30B | 11.13B | 9.68B |
| Long Term Investments | 20.15B | 18.72B | 2.91B | 2.86B |
| Property/Plant Equipment | 15.28B | 15.01B | 14.79B | 14.75B |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 35.37B | 39B | 33.02B | 34.04B |
| Tangible Assets (Net) | -154.57B | -155.16B | -142.99B | -143.99B |
| Other Assets | 3.14B | 3.61B | 3.12B | 3.05B |
| Total Assets | 167.49B | 170.45B | 156.20B | 155.42B |
| Accounts Payable | 4.22B | 3.94B | 4B | 4.16B |
| Other Current Liabilities | 15.63B | 14.24B | 15.72B | 13.76B |
| Total Current Liabilities | 37.30B | 36.97B | 32.03B | 29.42B |
| Total Liabilities | 104.04B | 105.05B | 96.27B | 96.26B |
| Long Term Debt | 37B | 37.08B | 37.19B | 36.78B |
| Current Long Term Debt | 1.46B | 2.43B | 2.14B | 4.47B |
| Minority Interest | 10M | 4M | 10M | 6M |
| Common Stock | 5.53B | 5.53B | 5.56B | 5.56B |
| Treasury Stock | 110.80B | 110.80B | 110.79B | 110.78B |
| Retained Earnings | 97.67B | 100.11B | 94.44B | 93.39B |
| Capital Surplus | 87.43B | 87.10B | 86.96B | 86.64B |
| Shareholder Equity | 63.14B | 65.10B | 59.57B | 58.81B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Pfizer Inc. balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 1.17B | 3.56B | 2.70B | 2.30B |
| Receivables | 8.03B | 10.02B | 9.87B | 9.45B |
| Inventory | 7.51B | 8.18B | 8.07B | 8.15B |
| Current Assets | 49.93B | 41.58B | 37.30B | 34.84B |
| Other Current Assets | 15.56B | 6.14B | 5.93B | 5.81B |
| Short Term Investments | 17.66B | 13.68B | 10.73B | 9.12B |
| Long Term Investments | 2.77B | 6.44B | 6.60B | 6.95B |
| Property/Plant Equipment | 13.39B | 14.04B | 13.92B | 13.97B |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 35.21B | 45.31B | 46.58B | 47.69B |
| Tangible Assets (Net) | -139.37B | -145.39B | -147.65B | -148.75B |
| Other Assets | 2.80B | 2.98B | 2.90B | 2.90B |
| Total Assets | 159.42B | 167.84B | 164.98B | 164.61B |
| Accounts Payable | 4.67B | 4.30B | 4.20B | 3.88B |
| Other Current Liabilities | 17.09B | 14.55B | 13.90B | 12.86B |
| Total Current Liabilities | 31.86B | 29.01B | 32.16B | 27.37B |
| Total Liabilities | 95.66B | 96.17B | 94.86B | 94.07B |
| Long Term Debt | 32.91B | 33.65B | 28.94B | 31.83B |
| Current Long Term Debt | 4.78B | 4.26B | 4.26B | 4.76B |
| Minority Interest | 11M | 8M | 7M | 9M |
| Common Stock | 5.72B | 5.78B | 5.86B | 5.85B |
| Treasury Stock | 101.61B | 96.57B | 95.46B | 95.46B |
| Retained Earnings | 89.55B | 91.99B | 89.86B | 89.96B |
| Capital Surplus | 86.25B | 85.83B | 84.90B | 84.60B |
| Shareholder Equity | 63.41B | 71.32B | 69.78B | 70.18B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Pfizer Inc. balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 1.34B | 2.78B | 2.59B |
| Receivables | 8.22B | 10B | 9.48B |
| Inventory | 7.58B | 7.93B | 7.58B |
| Current Assets | 41.14B | 40.29B | 36.39B |
| Other Current Assets | 5.35B | 5.44B | 4.99B |
| Short Term Investments | 18.65B | 14.15B | 11.75B |
| Long Term Investments | 7.02B | 7.31B | 7.01B |
| Property/Plant Equipment | 13.87B | 13.51B | 13.39B |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 48.74B | 49.72B | 51.35B |
| Tangible Assets (Net) | -146.37B | -157.27B | -157.5B |
| Other Assets | 3.23B | 3.39B | 3.47B |
| Total Assets | 171.80B | 172.15B | 168.56B |
| Accounts Payable | 4.66B | 3.48B | 3.44B |
| Other Current Liabilities | 15.34B | 14.29B | 13.68B |
| Total Current Liabilities | 30.43B | 28.22B | 27.18B |
| Total Liabilities | 100.14B | 111.04B | 109.86B |
| Long Term Debt | 33.54B | 34.50B | 34.19B |
| Current Long Term Debt | 3.55B | 3.07B | 3.07B |
| Minority Interest | 15M | 18M | 5M |
| Common Stock | 5.98B | 5.96B | 5.95B |
| Treasury Stock | 89.43B | 89.42B | 89.42B |
| Retained Earnings | 85.29B | 75.04B | 74.11B |
| Capital Surplus | 84.28B | 83.83B | 83.37B |
| Shareholder Equity | 71.31B | 60.77B | 58.37B |
| Other Liabilities | N.A | N.A | N.A |
Pfizer Inc. cash flow (2020) (USD)
| November 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Net Income | 2.19B | 3.43B | 3.40B |
| Depreciation | 3.73B | 1.25B | 1.22B |
| Changes in Receivables | 884M | 753M | -1.16B |
| Changes in Inventories | 731M | N.A | N.A |
| Cash Change | -883M | -352M | 847M |
| Cash Flow | 8.78B | 3.55B | 3.13B |
| Capital Expenditures | -1.51B | -480M | -495M |
| Investments | N.A | -12.55B | 420M |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | -12.6B | -13.01B | -71M |
| Dividends Paid | N.A | -2.11B | -2.11B |
| Net Borrowings | 46.13B | 11.32B | 18M |
| Other Financing Cash Flows | N.A | -84M | -237M |
| Cash Flow Financing | 4.14B | 9.16B | -2.2B |
| Exchange Rate Effect | N.A | -55M | -15M |
Pfizer Inc. cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | -337M | 7.68B | 5.05B | 3.88B |
| Depreciation | 1.38B | 1.55B | 1.53B | 1.55B |
| Changes in Receivables | 715M | 354M | -194M | -1.57B |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | -1.5B | 1.01B | -182M | 793M |
| Cash Flow | 3.77B | 4.51B | 2.61B | 1.70B |
| Capital Expenditures | -726M | -662M | -588M | -618M |
| Investments | -2.17B | 4.80B | -1.43B | 8.10B |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -2.83B | -6.76B | -1.9B | 7.55B |
| Dividends Paid | -1.99B | -2B | -2B | -2.05B |
| Net Borrowings | -470M | 5.35B | 1.07B | 2.81B |
| Other Financing Cash Flows | -69M | -125M | -45M | -496M |
| Cash Flow Financing | -2.44B | 3.27B | -851M | -8.47B |
| Exchange Rate Effect | 9M | -13M | -40M | 12M |
Pfizer Inc. cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | -394M | 4.11B | 3.87B | 3.56B |
| Depreciation | 1.64B | 1.61B | 1.56B | 1.57B |
| Changes in Receivables | 2B | -151M | -421M | -1.23B |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | -2.43B | 848M | 395M | 0.99B |
| Cash Flow | 4.74B | 5.26B | 3.85B | 1.98B |
| Capital Expenditures | -792M | -562M | -456M | -386M |
| Investments | -10M | -2.45B | -1.13B | 10.03B |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -764M | -2.9B | -1.47B | 9.67B |
| Dividends Paid | -1.96B | -1.99B | -1.99B | -2.03B |
| Net Borrowings | 462M | 790M | 316M | -2.5B |
| Other Financing Cash Flows | -36M | 278M | -337M | -494M |
| Cash Flow Financing | -6.41B | -1.41B | -1.91B | -10.72B |
| Exchange Rate Effect | N.A | -101M | -70M | 55M |
Pfizer Inc. cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | 12.27B | 2.84B | 3.07B |
| Depreciation | 1.57B | 1.57B | 1.57B |
| Changes in Receivables | 1.78B | -526M | -584M |
| Changes in Inventories | N.A | N.A | N.A |
| Cash Change | -1.44B | 194M | -1.47B |
| Cash Flow | 6.74B | 4.89B | 3.25B |
| Capital Expenditures | -773M | -597M | -489M |
| Investments | -4.14B | -2.46B | -0.99B |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | -4.78B | -3B | -1.74B |
| Dividends Paid | -1.91B | -1.9B | -1.91B |
| Net Borrowings | -1.67B | -84M | -1.18B |
| Other Financing Cash Flows | -10M | 5M | -8M |
| Cash Flow Financing | -3.39B | -1.73B | -3B |
| Exchange Rate Effect | -14M | 30M | 16M |
Pfizer Inc. dividends (USD)
| Ex date | Payment date | Record date | Declared date | Amount | Description | Frequency |
|---|---|---|---|---|---|---|
| 05-11-2020 | 01-12-2020 | 06-11-2020 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 30-07-2020 | 01-09-2020 | 31-07-2020 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 30-07-2020 | 01-09-2020 | 31-07-2020 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 07-05-2020 | 05-06-2020 | 08-05-2020 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 30-01-2020 | 06-03-2020 | 31-01-2020 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 07-11-2019 | 02-12-2019 | 08-11-2019 | N.A | 0.36 | Ordinary Shares | Quarterly |
| 01-08-2019 | 03-09-2019 | 02-08-2019 | N.A | 0.36 | Ordinary Shares | Quarterly |
| 09-05-2019 | 07-06-2019 | 10-05-2019 | N.A | 0.36 | Ordinary Shares | Quarterly |
| 31-01-2019 | 01-03-2019 | 01-02-2019 | N.A | 0.36 | Ordinary Shares | Quarterly |
| 08-11-2018 | 03-12-2018 | 09-11-2018 | N.A | 0.34 | Ordinary Shares | Quarterly |
| 02-08-2018 | 04-09-2018 | 03-08-2018 | N.A | 0.34 | Ordinary Shares | Quarterly |
| 10-05-2018 | 01-06-2018 | 11-05-2018 | N.A | 0.34 | Ordinary Shares | Quarterly |
| 01-02-2018 | 01-03-2018 | 02-02-2018 | N.A | 0.34 | Ordinary Shares | Quarterly |
| 09-11-2017 | 01-12-2017 | 10-11-2017 | N.A | 0.32 | Ordinary Shares | Quarterly |
| 02-08-2017 | 01-09-2017 | 04-08-2017 | N.A | 0.32 | Ordinary Shares | Quarterly |
| 10-05-2017 | 01-06-2017 | 12-05-2017 | N.A | 0.32 | Ordinary Shares | Quarterly |
| 01-02-2017 | 01-03-2017 | 03-02-2017 | N.A | 0.32 | Ordinary Shares | Quarterly |
| 08-11-2016 | 01-12-2016 | 11-11-2016 | N.A | 0.30 | Ordinary Shares | Quarterly |
| 03-08-2016 | 01-09-2016 | 05-08-2016 | N.A | 0.30 | Ordinary Shares | Quarterly |
| 11-05-2016 | 01-06-2016 | 13-05-2016 | N.A | 0.30 | Ordinary Shares | Quarterly |
| 03-02-2016 | 02-03-2016 | 05-02-2016 | N.A | 0.30 | Ordinary Shares | Quarterly |
| 04-11-2015 | 01-12-2015 | 06-11-2015 | N.A | 0.28 | Ordinary Shares | Quarterly |
| 05-08-2015 | 02-09-2015 | 07-08-2015 | N.A | 0.28 | Ordinary Shares | Quarterly |
Total Valuation
Pfizer Inc. has a market cap or net worth of $243.22 billion. The enterprise value is $261.69 billion.
Market Cap
243.22B
Enterprise Value
261.69B
Important Dates
Earnings Date
Jul 28, 2021
Ex-Dividend Date
n.a
Share Statistics
Pfizer Inc. has 5.60 billion shares outstanding.
Shares Outstanding
5.60B
Float
n.a
Valuation Ratios
The trailing PE ratio is 21.2500 and the forward PE ratio is 56.5101. Pfizer Inc.'s PEG ratio is -0.7132.
PE Ratio
21.2500
Forward PE
56.5101
PS Ratio
5.3000
PB Ratio
3.4300
PEG Ratio
-0.7132
Stock Price Statistics
The stock price has increased by 0.1675%. The beta is 0.4805, so Pfizer Inc.'s price volatility has been lower than the market average.
Beta (1Y)
0.4805
52-Week Price Change
+0.1675%
50-Day Moving Average
39.91
200-Day Moving Average
37.40
Average Volume (30 Days)
22.68M
Income Statement
In the last 12 months, Pfizer Inc. had revenue of $44.46 billion and earned $33.94 billion in profits. Earnings per share was $1.96.
Revenue
44.46B
Gross Profit
33.94B
EBITDA
14.38B
Earnings per Share
1.96
About
Country
United States
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Employees
78,500
CEO
Albert Bourla
Address
235 E 42nd St
New York
New York
10017-5703
New York
New York
10017-5703
Phone
12125732323
Website
www.pfizer.com
Ticker Symbol
PFE
Reporting Currency
USD
Company Description
Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. It strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with its responsibility as one of the world's premier innovative biopharmaceutical companies, it collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.
For more than 150 years, it has worked to make a difference for all who rely on it. It routinely posts information that may be important to investors on its website at www.Pfizer.com..